Batra Hitesh, Antony Veena B
Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham Birmingham, AL, USA.
J Thorac Dis. 2015 Jun;7(6):964-80. doi: 10.3978/j.issn.2072-1439.2015.02.19.
During development, the mesoderm maintains a complex relationship with the developing endoderm giving rise to the mature lung. Pleural mesothelial cells (PMCs) derived from the mesoderm play a key role during the development of the lung. The pleural mesothelium differentiates to give rise to the endothelium and smooth muscle cells via epithelial-to-mesenchymal transition (EMT). An aberrant recapitulation of such developmental pathways can play an important role in the pathogenesis of disease processes such as idiopathic pulmonary fibrosis (IPF). The PMC is the central component of the immune responses of the pleura. When exposed to noxious stimuli, it demonstrates innate immune responses such as Toll-like receptor (TLR) recognition of pathogen associated molecular patterns as well as causes the release of several cytokines to activate adaptive immune responses. Development of pleural effusions occurs due to an imbalance in the dynamic interaction between junctional proteins, n-cadherin and β-catenin, and phosphorylation of adherens junctions between PMCs, which is caused in part by vascular endothelial growth factor (VEGF) released by PMCs. PMCs play an important role in defense mechanisms against bacterial and mycobacterial pleural infections, and in pathogenesis of malignant pleural effusion, asbestos related pleural disease and malignant pleural mesothelioma. PMCs also play a key role in the resolution of inflammation, which can occur with or without fibrosis. Fibrosis occurs as a result of disordered fibrin turnover and due to the effects of cytokines such as transforming growth factor-β, platelet-derived growth factor (PDGF), and basic fibroblast growth factor; which are released by PMCs. Recent studies have demonstrated a role for PMCs in the pathogenesis of IPF suggesting their potential as a cellular biomarker of disease activity and as a possible therapeutic target. Pleural-based therapies targeting PMCs for treatment of IPF and other lung diseases need further exploration.
在发育过程中,中胚层与发育中的内胚层维持着复杂的关系,最终形成成熟的肺。源自中胚层的胸膜间皮细胞(PMC)在肺发育过程中起关键作用。胸膜间皮通过上皮-间充质转化(EMT)分化产生内皮细胞和平滑肌细胞。这种发育途径的异常重演在诸如特发性肺纤维化(IPF)等疾病过程的发病机制中可能起重要作用。PMC是胸膜免疫反应的核心组成部分。当暴露于有害刺激时,它会表现出天然免疫反应,如Toll样受体(TLR)对病原体相关分子模式的识别,还会导致多种细胞因子释放以激活适应性免疫反应。胸腔积液的形成是由于连接蛋白、N-钙黏蛋白和β-连环蛋白之间动态相互作用失衡,以及PMC之间黏附连接的磷酸化,部分原因是PMC释放的血管内皮生长因子(VEGF)所致。PMC在抵御细菌和分枝杆菌性胸膜感染的防御机制中以及在恶性胸腔积液、石棉相关胸膜疾病和恶性胸膜间皮瘤的发病机制中起重要作用。PMC在炎症消退过程中也起关键作用,炎症消退可伴有或不伴有纤维化。纤维化是由于纤维蛋白周转紊乱以及诸如转化生长因子-β、血小板衍生生长因子(PDGF)和碱性成纤维细胞生长因子等细胞因子的作用导致的,这些细胞因子由PMC释放。最近的研究表明PMC在IPF发病机制中起作用,提示它们作为疾病活动的细胞生物标志物以及可能的治疗靶点的潜力。针对PMC的基于胸膜的疗法用于治疗IPF和其他肺部疾病需要进一步探索。